Clinical Trials Logo

Digestive System Neoplasms clinical trials

View clinical trials related to Digestive System Neoplasms.

Filter by:

NCT ID: NCT05996458 Recruiting - Digestive Disease Clinical Trials

A Population-based, Multicenter Cohort Study of Combined Screening for Gastrointestinal Tumors

Start date: August 1, 2023
Phase:
Study type: Observational

To establish combined gastroenteroscopy screening and follow-up management for gastrointestinal tumors, explore and evaluate the feasibility and health economic benefits of combined screening for esophagus, stomach and colorectal cancer

NCT ID: NCT05981235 Recruiting - Clinical trials for Gastrointestinal Tumors

Phase 1 Trial of AZD6422 in CLDN18.2+ GI Tumors

Start date: December 14, 2023
Phase: Phase 1
Study type: Interventional

This is a FTiH, Phase 1 IIT to evaluate the safety, feasibility, cellular kinetics (CK), pharmacodynamics (PD), immunogenicity, and preliminary antitumor activity of AZD6422 in adult participants with advanced or metastatic CLDN18.2+ GI tumors.

NCT ID: NCT05980416 Recruiting - Neoplasms Clinical Trials

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Start date: August 10, 2023
Phase: Phase 1
Study type: Interventional

This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.

NCT ID: NCT05964543 Recruiting - Clinical trials for Gastroesophageal Junction (GEJ) Adenocarcinoma

The Safety and Efficacy of Q-1802 Combined With XELOX in Gastrointestinal Tumors

Start date: June 21, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The main purpose of this study is to evaluate safety, tolerability and the efficacy of Q-1802 plus SOC compared with SOC. .Pharmacokinetics (PK) ,Pharmacodynamics (PD) of Q-1802 and the immunogenicity profile of Q-1802 will be evaluated as well.

NCT ID: NCT05946226 Recruiting - Clinical trials for Advanced Digestive System Tumor

A Phase I Trial to Evaluate the Safety of IMC002 in Advanced Digestive System Tumors

Start date: September 7, 2023
Phase: Phase 1
Study type: Interventional

This is an open-label, multi-center, dose-escalation clinical study to evaluate the safety, feasibility, and preliminary efficacy of IMC002 in patients with CLDN18.2 positive digestive system tumors including but not limited to advanced gastric cancer, esophagogastric junction adenocarcinoma, and advanced pancreatic cancer.

NCT ID: NCT05913661 Recruiting - Carcinoma Clinical Trials

Pemigatinib Combined With PD-1 Inhibitor in Unresectable or Metastatic Intrahepatic Cholangiocarcinoma

Start date: July 2023
Phase: Phase 2
Study type: Interventional

This is a Prospective, single-arm, phase II study with multicenter participation. The objective of this study is to evaluate the efficacy and safety of pemigatinib combined with PD-1 inhibitor as first-line treatment for patients with advanced unresectable or metastatic intrahepatic cholangiocarcinoma.

NCT ID: NCT05772546 Recruiting - Clinical trials for Gastrointestinal Cancer

Avatrombopag vs. Placebo for CIT in GI Malignancies

ACT-GI
Start date: November 1, 2023
Phase: Phase 2
Study type: Interventional

The purpose of this study is to compare the efficacy of two study drugs, Avatrobopag versus placebo, to treat persistent Chemotherapy-Induced Thrombocytopenia (CIT) in patients with gastrointestinal (GI) malignancies receiving cytotoxic chemotherapy. The names of the study drugs involved in this study are: - Avatrombopag (a thrombopoietin receptor agonist) - Matching placebo

NCT ID: NCT05646043 Recruiting - Cancer, Rectum Clinical Trials

PREHAB - Improving Condition Before Surgery

Start date: December 1, 2022
Phase: N/A
Study type: Interventional

The pilot research project is focused on the feasibility of a prehabilitation program for two groups of diagnoses (esophageal and stomach cancer, rectal cancer).

NCT ID: NCT05639153 Recruiting - Clinical trials for Malignant Neoplasm of Digestive System

A Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of DR30303 in Patients With Advanced Solid Tumors

Start date: May 13, 2022
Phase: Phase 1
Study type: Interventional

This study is an open-label Phase 1, First in Human trial of DR30303, a recombinant humanized monoclonal antibody that targets Claudin18.2 (CLDN18.2). It is composed of humanized variable domain of heavy chain of antibody (VHH) fused with engineered immunoglobulin gamma-1(IgG1) Fc. It is being testing against advanced and/or metastatic solid tumors.

NCT ID: NCT05636618 Recruiting - Clinical trials for Neuroendocrine Tumors

Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors

212-Pb-VMT
Start date: September 27, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors